MedTrace Logo

Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

NCT06567314 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-04-20

No results posted yet for this study

Summary

To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.

Conditions

Interventions

DRUG

Ivonescimab

Given by PO

Sponsors & Collaborators

  • Summit Therapeutics

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Aung Naing, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-02
Primary Completion
2028-09-01
Completion
2030-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06567314 on ClinicalTrials.gov